{"id":996867,"date":"2026-08-20T07:06:19","date_gmt":"2026-08-20T11:06:19","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/harrow-announces-iheezo-data-in-patient-reported-discomfort-following-intravitreal-injections\/"},"modified":"2026-08-20T07:06:19","modified_gmt":"2026-08-20T11:06:19","slug":"harrow-announces-iheezo-data-in-patient-reported-discomfort-following-intravitreal-injections","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/harrow-announces-iheezo-data-in-patient-reported-discomfort-following-intravitreal-injections\/","title":{"rendered":"Harrow Announces IHEEZO\u00ae Data in Patient-Reported Discomfort Following Intravitreal Injections"},"content":{"rendered":"

\nPatients reported approximately 58% less discomfort overall in the IHEEZO-treated eye, with the largest absolute differences in the immediate post-injection period, when discomfort is highest
\n<\/h2>\n
\n

NASHVILLE, Tenn., Aug. 20, 2026 (GLOBE NEWSWIRE) — Harrow (Nasdaq: HROW), a leading provider of ophthalmic disease management solutions in North America, today announced positive results from a prospective, randomized, contralateral-eye study evaluating IHEEZO\u00ae<\/sup> (chloroprocaine hydrochloride ophthalmic gel) 3%, an ophthalmic gel indicated for ocular surface anesthesia, in patients undergoing same-day bilateral intravitreal injections. The single-center, investigator-initiated study demonstrated statistically significant differences favoring IHEEZO at every measured time point.<\/p>\n

Patients reported approximately 58% less discomfort overall in the IHEEZO-treated eye than in the fellow eye treated with proparacaine ophthalmic solution 0.5%, a statistically significant difference at all four post-injection assessments (all p\u22640.048). The largest absolute treatment differences were observed immediately after injection, when discomfort is highest: 1.44 versus 3.06 at two minutes and 1.26 versus 2.82 at one hour, while lower discomfort scores with IHEEZO remained evident through the 24-hour assessment.<\/p>\n

Millionsi<\/sup> of intravitreal injections are performed in the United States each year \u2014 making them among the most frequently performed procedures in ophthalmology \u2014 and they are often administered repeatedly over months or years to patients with retinal diseases. As a result, the injection experience, including patient discomfort, can become an important consideration for both patients and retina specialists, particularly in practices managing a high volume of patients who return regularly for treatment.<\/p>\n

\n Study Results<\/strong>\n <\/p>\n

IHEEZO was associated with lower patient-reported discomfort at all four post-injection assessments, measured using a standard 0-to-10 numeric rating scale:<\/p>\n

\n \n <\/p>\n

The results showed a consistent benefit with IHEEZO throughout the 24-hour assessment period, with lower patient-reported discomfort at every time point. The largest absolute differences occurred shortly after injection, when discomfort is highest. Absolute treatment differences were 1.62 points at two minutes and 1.56 points at one hour, and lower discomfort scores with IHEEZO remained evident through the 24-hour assessment.<\/p>\n

\u201cPatient comfort is a larger part of the intravitreal injection experience than it is sometimes given credit for,\u201d said Travis Peck, MD, Retina Consultants of Delmarva, principal investigator of the study. \u201cBecause each patient received both anesthetic approaches on the same day, we were able to directly compare the patient experience. Patients consistently reported less discomfort in the IHEEZO-treated eye across all time points we measured. For retina specialists who perform a high volume of injections and care for patients who return repeatedly for treatment, these are practical and clinically relevant findings.\u201d<\/p>\n

\u201cThese results provide new clinical evidence from a real-world practice setting supporting IHEEZO\u2019s differentiated clinical profile versus commonly administered legacy ophthalmic anesthesia modalities \u2013 demonstrating a measurable improvement in patient-reported comfort following intravitreal injections,\u201d said Mark L. Baum, Chief Executive Officer of Harrow. \u201cRetina specialists work to preserve vision in patients who require ongoing treatment over many years, and the experience of each of those visits matters and ideally, should be optimized. The consistency and magnitude of the reduction in patient discomfort should strengthen physician confidence in IHEEZO\u2019s clinical profile and support broader utilization of the product across retina practices.\u201d<\/p>\n

\n About the Study<\/strong>\n <\/p>\n

The investigator-initiated study was a prospective, randomized, contralateral-eye comparison conducted in a private retina practice. The study evaluated 100 eyes from 50 adult patients undergoing same-day bilateral intravitreal injections. Both eyes received 2% lidocaine-soaked pledgets prior to administration of the randomized study anesthetic. In each patient, one randomly assigned eye received IHEEZO prior to injection and the fellow eye received preservative-containing proparacaine ophthalmic solution 0.5%, allowing each patient to serve as his or her own control and reducing between-patient variability.<\/p>\n

Patient-reported ocular discomfort was assessed using a 0-to-10 numeric rating scale at 2 minutes, 1 hour, 6\u201312 hours, and 24 hours following injection.<\/p>\n

\n IHEEZO\u00ae<\/sup> (chloroprocaine\u202fhydrochloride ophthalmic gel) 3%, for topical ophthalmic use<\/strong>\n <\/p>\n

\n INDICATIONS AND USAGE<\/strong>\n <\/p>\n

IHEEZO is an ester anesthetic indicated for ocular surface anesthesia.<\/p>\n

\n IMPORTANT SAFETY INFORMATION<\/strong>\n <\/p>\n

\n CONTRAINDICATIONS<\/strong>\n <\/p>\n

IHEEZO is contraindicated in patients with a history of hypersensitivity to any\u202fcomponent\u202fof\u202fthis preparation<\/p>\n

\n WARNINGS AND PRECAUTIONS<\/strong>\n <\/p>\n